| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:(R)-(+)-HA-966;(R)-(+)-3-AMino-1-hydroxypyrrolidin-2-one
CAS:123931-04-4
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
|
| | (R)-(+)-HA-966 Basic information |
| Product Name: | (R)-(+)-HA-966 | | Synonyms: | R(+)-HA-966 R(+)-3-AMINO-1-HYDROX;(R)-(+)-HA-966;R(+)-3-AMINO-1-HYDROXY-2-PYRROLIDINONE;(R)-(+)-3-AMINO-1-HYDROXYPYRROLIDIN-2-ONE;Zinc03791818;(3R)-3-Amino-1-hydroxy-2-pyrrolidinone;(R)-3-amino-1-hydroxypyrrolidin-2-one 2,2,2-trifluoroacetate;2-Pyrrolidinone, 3-amino-1-hydroxy-, (3R)- | | CAS: | 123931-04-4 | | MF: | C4H8N2O2 | | MW: | 116.12 | | EINECS: | | | Product Categories: | Glutamate receptor | | Mol File: | 123931-04-4.mol |  |
| | (R)-(+)-HA-966 Chemical Properties |
| Melting point | 166℃ | | Boiling point | 258.6±50.0 °C(Predicted) | | density | 1.436±0.06 g/cm3(Predicted) | | storage temp. | Desiccate at RT | | solubility | H2O: soluble | | pka | 7.19±0.20(Predicted) | | form | solid | | color | white | | Optical Rotation | [α]22/D +103°, c = 1 in H2O(lit.) | | Water Solubility | Soluble to 100 mM in water |
| | (R)-(+)-HA-966 Usage And Synthesis |
| Uses | (R)-(+)-HA-966 is an antagonist/partial agonist at the glycine site of the NMDA receptor. | | Biological Activity | Antagonist/partial agonist at the glycine site of the NMDA receptor; able to cross the blood-brain barrier. Also available as part of the NMDA Receptor - Glycine Site Tocriset™ . | | in vivo | (R)-(+)-HA-966 ((+)-HA-966; 10 mg/kg; IV) significantly attenuates the dose-dependent pressor response and the associated tachycardic response elicited by systemic NMDA (125, 250, 500, and 1000 mg/kg; i.v.)[3].
(+)-HA-966 (30, 100 mg/kg; IP) dose-dependently blocks the enhancement of dopamine synthesis induced in the nucleus accumbens by amphetamine, but is without effect on the increase in dopamine synthesis in the striatum in male BKTO mice (20-30g)[1].
| Animal Model: | Sprague-Dawley rats (11 to 12 weeks old)[3] | | Dosage: | 10 mg/kg | | Administration: | IV | | Result: | Significantly attenuated the dose-dependent pressor response and the associated tachycardic response elicited by systemic NMDA.
|
| | IC 50 | NMDA Receptor | | storage | Desiccate at RT |
| | (R)-(+)-HA-966 Preparation Products And Raw materials |
|